Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of December 2017, with the report signed on December 22, 2017. The filing serves as a Change of Director's Interest Notice under ASX Listing Rule 3.19A.2 and Section 205G of the Corporations Act. The registrant is a foreign private issuer based in Parkville, Victoria, Australia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial statements or performance metrics.
Material Changes
The filing discloses a material change in the securities held by Director Mr. Brian Meltzer on December 19, 2017:
- Options Lapsed: 1,000,000 direct unlisted options lapsed.
- Options Acquired: 1,250,000 unlisted options were acquired via the employer share option plan.
- Shareholdings: Mr. Meltzer holds 326,666 shares (indirect interest) and 0 direct shares. No shares were acquired or disposed of in this transaction.
- Net Position: Following the change, Mr. Meltzer holds a total of 326,666 shares and 1,250,000 options.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, or contingencies. The document references an Explanatory Memorandum from the 2017 Notice of Annual General Meeting regarding the consideration for the options but does not include the content of that memorandum. The transaction was not conducted during a closed period.
Investor Verification Checklist
- Verify the terms and exercise price of the 1,250,000 new options granted to Mr. Meltzer in the referenced 2017 AGM Explanatory Memorandum.
- Confirm the reason for the lapse of the previous 1,000,000 options held by Mr. Meltzer.
- Review the company's latest financial reports (Form 20-F) for actual revenue and liquidity data, as this filing contains none.
- Check for any other director interest changes filed around the same period to assess overall insider sentiment.